Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
A1KZ92
UPID:
PXDNL_HUMAN
Alternative names:
Cardiac peroxidase; Inactive peroxidasin-like protein; Polysomal ribonuclease 1; Vascular peroxidase 2
Alternative UPACC:
A1KZ92; B5ME43; B6CGZ3; H0YBM9; Q6ZMR2; Q96LH9
Background:
Probable oxidoreductase PXDNL, also known as Cardiac peroxidase, Inactive peroxidasin-like protein, and Vascular peroxidase 2, plays a crucial role in cellular processes. It functions as a probable oxidoreductase and is known to inhibit the peroxidase activity of PXDN. Additionally, it acts as an endonuclease, degrading specific target mRNAs, including albumin and beta-globin, during translation.
Therapeutic significance:
Understanding the role of Probable oxidoreductase PXDNL could open doors to potential therapeutic strategies.